NEW YORK (GenomeWeb News) – Accelr8 today disclosed that revenues during its fiscal third quarter fell 18-fold quarter over quarter, resulting from the end of an agreement with Novartis.
In its Form 10-Q filed with the US Securities and Exchange Commission, the Denver-based company reported revenues of $13,207 for the three months ended April 30, compared to $240,272 a year ago, as technical development fees came in at $0 for the recent quarter, down from $214,500 a year ago.